{"filing":{"accession_number":"0001728117-26-000054","cik":"0001728117","ticker":"GOSS","company_name":"Gossamer Bio, Inc.","form":"8-K","filing_date":"2026-06-17","report_date":null,"primary_document":"goss-20260617.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1728117/000172811726000054/goss-20260617.htm"},"events":[{"id":11446,"run_id":10049,"accession_number":"0001728117-26-000054","anchor_item_number":"7.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Gossamer Bio announced final tender results for a material exchange offer involving the conversion of $72.0 million in 5.00% Convertible Senior Notes due 2027 into new 7.50% Convertible Senior Secured First Lien Notes due 2030, up to 317.6 million shares of common stock, and warrants. This constitutes a material capital restructuring and debt refinancing transaction that materially alters the company's capital structure and obligations, requiring stockholder approval at a special meeting on July 14, 2026.","company_name":"Gossamer Bio, Inc.","ticker":"GOSS","filing_date":"2026-06-17","form":"8-K","submitted_at":null,"items":[{"id":8037,"accession_number":"0001728117-26-000054","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Gossamer Bio announced final tender results for a material exchange offer involving the conversion of $72.0 million in 5.00% Convertible Senior Notes due 2027 into new 7.50% Convertible Senior Secured First Lien Notes due 2030, up to 317.6 million shares of common stock, and warrants. This constitutes a material capital restructuring and debt refinancing transaction that materially alters the company's capital structure and obligations, requiring stockholder approval at a special meeting on July 14, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T12:02:11.259883+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8037,"accession_number":"0001728117-26-000054","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Gossamer Bio announced final tender results for a material exchange offer involving the conversion of $72.0 million in 5.00% Convertible Senior Notes due 2027 into new 7.50% Convertible Senior Secured First Lien Notes due 2030, up to 317.6 million shares of common stock, and warrants. This constitutes a material capital restructuring and debt refinancing transaction that materially alters the company's capital structure and obligations, requiring stockholder approval at a special meeting on July 14, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T12:02:11.259883+00:00","company_name":"Gossamer Bio, Inc.","ticker":"GOSS","filing_date":"2026-06-17"}]}